Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Slides:

Advertisements

Similar presentations

Initiating Antiretroviral Therapy in Treatment-Naive Patients Charles B. Hicks, MD Associate Professor of Medicine, Division of Infectious Diseases and.

Advertisements

Combination Antiretroviral Therapy for HIV Infection by Ormrat Kampeerawipakorn.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Global HIV Resistance: The Implications of Transmission

UK-CAB Jan05 BHIVA treatment guidelines UK-CAB - 28 Jan 2005 Simon Collins, HIV i-Base.

Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.

Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation J. M. Schapiro, J. Vingerhoets, S.

ARV Therapy Basics in the Context of Family Planning

Enfuvirtide for Drug-Resistant HIV Infection in North and South America Simon R. Bababeygy.

Management of NRTI Resistance

Background: Ritonavir-boosted protease-inhibitor (PI)-monotherapies are an attractive alternative to conventional therapy in order to avoid the potential.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Frequency HIV-1 Drug Resistance Mutations and.

Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)

Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.

Human Immunodeficiency Virus – HIV and the correctional system.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Monotherapy or Dual Therapy in Switch Studies: Which is the Best Regimen? Dr. Jose R

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral.

A. Timeline of select milestones in HIV management

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

AIDS Chien-Ming Li MD, Ph.D.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Figure 1. Prevalence of undocumented hepatitis C virus (HCV) infection, by age, race, and sex in 4713 emergency department patients, From: Evaluation.

Introduction Results Objectives Methods Conclusion Funding

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

From: Postinfectious Irritable Bowel Syndrome

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2

Table 1 Baseline (before receipt of antiretroviral prophylaxis) characteristics of the pregnant women (transmitting or nontransmitting mothers included.

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses

Switch to DTG + 3TC ASPIRE Study.

Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive.

HIV Prevention and Treatment: The Evolving Role of the Emergency Department Kristi Stanley, MD, Meredith Lora, MD, Stephen Merjavy, MD, Jennifer Chang,

M. Colafigli, C. Torti, E. M. Trecarichi, L. Albini, A. Rosi, V

Switch to DRV/r + 3TC DUAL Study.

St Stephen’s Centre, Chelsea & Westminster Hospital, United Kingdom

Analysis of transmitted drug resistance in Spain in the years 2007–2010 documents a decline in mutations to the non-nucleoside drug class S. Monge, V.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Drug-resistant human immunodefiency virus

Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure

Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.

Analysis of intracellular human immunodeficiency virus (HIV)-1 drug resistance mutations in multi-failed HIV-1-infected patients treated with a salvage.

Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.

Replication life cycle of HIV and sites of antiretroviral drug action.

Switch to LPV/r monotherapy

G. Rocheleau, C.J. Brumme, J. Shoveller, V.D. Lima, P.R. Harrigan

Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009 S. Di Giambenedetto, M. Prosperi, I.

Volume 377, Issue 9777, Pages (May 2011)

F. Ceccherini-Silberstein, V. Cento, V. Calvez, C.-F. Perno

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

New patterns of HIV-1 resistance during HAART

Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy M. Franzetti, M.

Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.

ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE

Dr. Grace Namayanja – Kaye 24 July 2019

Presentation transcript:

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; VL, viral load. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

Figure 2 Flow diagram of reviewed literature. PK, pharmacokinetic. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

Table 1 Characteristics of the study and intention-to-treat (ITT) populations. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

Table 2 Nucleoside reverse-transcriptase inhibitor (NRTI) backbone distribution and pooled resistance data at week 48 for ritonavir-boosted protease inhibitor (PI)- and non-NRTI (NNRTI)-based HAART regimens. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

Figure 3 Virologic failures in studies of nonnucleoside reverse-transcriptase inhibitor (NNRTI) and ritonavir-boosted protease inhibitor (bPI) HAART. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

Figure 4 Week 48 incidence of genotypic resistance at virologic failure. A, Intention-to-treat analysis. B, Genotype analysis. NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America

Figure 5 Week 96 incidence of genotypic resistance at virologic failure. A, Intention-to-treat analysis). B, Genotype analysis. NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutation. From: Emergence of Drug Resistance in HIV Type 1-Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials Clin Infect Dis. 2008;47(5):712-722. doi:10.1086/590943 Clin Infect Dis | © 2008 by the Infectious Diseases Society of America